E2F activity-inhibiting compound
    71.
    发明申请
    E2F activity-inhibiting compound 审中-公开
    E2F活性抑制化合物

    公开(公告)号:US20050137138A1

    公开(公告)日:2005-06-23

    申请号:US10752505

    申请日:2004-01-08

    CPC分类号: C07K14/4705 A61K38/00

    摘要: E2F-inhibiting compounds are represented by the general formula: R1-A-R2 wherein A represents a peptide sequence comprising a partial amino acid sequence having at least 12 continuous residues in the sequence of the dimerization region or DNA binding region of the E2F family), which are useful as a therapeutic agent of diseases such as tumor and arteriosclerosis, for which abnormal cellular growth is responsible.

    摘要翻译: E2F抑制化合物由以下通式表示:其中A表示包含部分氨基酸序列的肽序列,所述部分氨基酸序列具有至少12个连续残基 E2F家族的二聚化区域或DNA结合区域的序列),其可用作肿瘤和动脉硬化疾病的治疗剂,异常细胞生长负责。

    Platelet production promoting agent
    76.
    发明授权
    Platelet production promoting agent 有权
    血小板生产促进剂

    公开(公告)号:US07592311B2

    公开(公告)日:2009-09-22

    申请号:US11253617

    申请日:2005-10-20

    IPC分类号: A61K38/00 A61K38/17

    CPC分类号: C07K14/535 A61K38/00

    摘要: The invention relates to a polypeptide wherein at least one of the amino, carboxyl, mercapto or guanidino group in a polypeptide molecule having human granulocyte colony stimulating factor activity is chemically modified by a chemical modifying agent, and a platelet production promoter comprising said polypeptide, a method for treating a patient with decreased platelet counts comprising administering an effective amount of said polypeptide to the patient, the use of said polypeptide for the production of pharmaceutical compositions which are useful for the treatment of the patient with decreased platelet counts, and the compositions for treating the patient with decreased platelet counts, which comprises an effective dose of said polypeptide in a pharmaceutically acceptable dosage form with a pharmaceutical acceptable carrier.

    摘要翻译: 本发明涉及一种多肽,其中具有人粒细胞集落刺激因子活性的多肽分子中的氨基,羧基,巯基或胍基中的至少一个被化学修饰剂化学修饰,并且包含所述多肽的血小板产生启动子, 用于治疗血小板计数降低的患者的方法包括向患者施用有效量的所述多肽,所述多肽用于制备可用于治疗血小板计数减少的患者的药物组合物的用途,以及用于 用减少的血小板计数治疗患者,其包含药学上可接受的剂型中的有效剂量的所述多肽与药学上可接受的载体。